RBC Capital alza il target su CG Oncology a 79$ per trial promettente

AI Briefing

• – RBC Capital raises target price on CG Oncology to $79 on promising trial
• – The analyst firm set a new price target on the company's stock
• – The move reflects the strong clinical data from the trial